Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study to see if antivirals help immunocompromised COVID patients

NCT ID NCT06683937

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will review medical records of 300 immunocompromised adults hospitalized with COVID-19 in France between June 2023 and April 2024. Researchers want to see how well antiviral drugs like nirmatrelvir/ritonavir and remdesivir work in these patients. The goal is to track their recovery and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nirmatrelvir/ritonavir or remdesivir
What this could lead to
If successful, this could help doctors understand which antiviral treatments work best for immunocompromised patients with COVID-19.
What could go wrong
This is an observational study that only looks back at medical records, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients at very high risk of severe SARS-CoV-2 disease, hospitalized for SARS-CoV-2 infection from June 2023 to April 2024 in France.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with SARS-CoV-2 in France, treated in a center participating in the study * Symptomatic patients for Covid-19 who have received mono- or dual therapy with nirmatrelvir/ritonavir or remdesivir * SARS-CoV-2 positive by PCR on nasopharyngeal swab, ECBC or bronchoalveolar fluid * Hospitalization in a ward or day hospital for SARS-CoV-2 infection * Patients at very high risk of severe form of SARS-CoV-2 * Aggressive lymphomas (all types) * Acute lymphocytic leukemia * Acute myeloid leukemia * Acute promyelocytic leukemia * T-cell prolymphocytic leukemia * Primary lymphoma of the central nervous system * Stem cell transplant * Light chain amyloidosis * Chronic lymphocytic leukemia * Multiple myeloma * Hematopoietic stem cell transplant * Solid organ transplant * Being on the waiting list for an organ transplant * Primary immunodeficiency; * HIV patients with CD4 \<200/mm3 or with a detectable viral load * Lymphopenia \<200/mm3 * Neutropenia \<1000/mm3 for \> 1 week * Patients receiving long-term immunosuppressive treatment (period of at least 3 months during treatment during infection) with: * anti-CD20 antibodies * anti-JAK * BTK inhibitors * azathioprine * cyclophosphamide * methotrexate * mycophenolate mofetil * CAR-T cell gene therapy * bi-phenotypic therapeutic antibodies * tacrolimus * sirolimus * long-term corticosteroids (prednisone equivalent dose \>5mg for 3 months) Exclusion Criteria: * Opposition formulated (following receipt of the study information note) * Patients who received convalescent plasma as first-line treatment for SARS-CoV-2 infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunocompromised patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunocompromised patients SARS-CoV-2 disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH Périgueux

    Périgueux, 24000, France

  • CHD Vendée (La Roche sur Yon)

    La Roche-sur-Yon, 85000, France

  • CHRU Lille

    Lille, 59000, France

  • CHU Angers

    Angers, 49000, France

  • CHU Caen

    Caen, 14000, France

  • CHU Nantes

    Nantes, 44000, France

  • CHU Nord Marseille

    Marseille, 13000, France

  • CHU Nîmes Caremeau

    Nîmes, 30000, France

  • CHU Poitiers

    Poitiers, 86000, France

  • CHU Reims

    Reims, 51100, France

  • CHU Sud Réunion

    Saint-Pierre, 97410, France

  • CHU Toulouse

    Toulouse, 31000, France

  • Hôpital Bichat

    Paris, 75018, France

  • Hôpital Necker-Enfants Malades

    Paris, 75015, France

  • Hôpital Pasteur, Colmar

    Colmar, 68000, France

  • Hôpital Saint-Louis

    Paris, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.